12 completed, 1 no longer available, 1 terminated, 1 unknown. 8 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 1, Unknown 1 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 4 | Completed 4 |
Follow Ad26.COV2.S: new trials by email Literature Review of Ad26.COV2.S trials Research Report on Ad26.COV2.S
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine Ad26.COV2.S - COVID-19, Vaccine Reaction | Phase 2 | Unknown | ANRS, Emerging Infectious Diseases | 200 | 2022-06-02 | 2024-03-27 |
| A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults Ad26.COV2.S, Placebo, Influenza Vaccine - COVID-19 Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 861 | 2021-11-02 | 2025-05-25 |
| A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive Ad26.COV2.S - Coronavirus Disease-2019 (COVID-19) Prevention | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 304 | 2021-09-27 | 2025-02-04 |
| A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) Ad26.COV2.S - COVID-19 Prevention | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 51 | 2021-08-27 | 2025-05-25 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 Ad26.COV2.S - Coronavirus Disease | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 1541 | 2021-08-06 | 2025-02-04 |
| A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults Ad26.COV2.S - COVID-19 Prevention | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 1609 | 2021-06-18 | 2025-02-04 |
| Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19 | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 867 | 2021-05-28 | 2025-04-20 |
| A Study of Ad26.COV2.S in Healthy Adults (COVID-19) Ad26.COV2.S - Healthy | Phase 1 | Completed | Janssen Vaccines & Prevention B.V. | 380 | 2021-05-25 | 2021-12-22 |
| A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Ad26.COV2.S, Placebo - Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 31835 | 2020-11-12 | 2025-02-04 |
| A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants Ad26.COV2.S, Placebo - Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 44325 | 2020-09-07 | 2025-02-04 |
| A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents Ad26.COV2.S, Placebo - Healthy | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 635 | 2020-08-28 | 2023-06-22 |
| A Study of Ad26.COV2.S in Adults (COVID-19) Ad26.COV2.S, Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 250 | 2020-08-11 | 2021-11-24 |
| A Study of Ad26.COV2.S in Adults (COVID-19) Ad26.COV2.S, Placebo - Covid-19 Prevention | Phase 1 / Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 1085 | 2020-07-15 | 2025-02-04 |
| Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use Ad26.COV2.S - Healthy | No longer available | Janssen Research & Development, LLC | 2021-03-26 |
COVID-19 (5) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Dermatomyositis (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Pemphigus (1) · Scleroderma, Systemic (1)
Janssen Vaccines & Prevention B.V. (10) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ANRS, Emerging Infectious Diseases (1) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1)
United States (9) · Brazil (5) · South Africa (5) · Belgium (3) · Germany (3) · Argentina (2) · Colombia (2) · Mexico (2) · Netherlands (2) · Poland (2) · Spain (2) · United Kingdom (2) · Chile (1) · France (1) · India (1)
Amit Bar-Or, MD, FRCP (1) · Dinesh Khanna, MBBS, MSc (1) · Judith A. James, MD, PhD (1) · Kirsten E Lyke, M.D. (1) · Meggan C. Mackay, MD, MS (1) · Natasha Mckerran Ruth, MD (1) · Odile Launay (1) · Robert L Atmar, M.D. (1) · Samba Sow (1) · Stacy Ardoin, MD (1) · Tracey Wright, MD (1) · Virginia Pascual, MD (1)
PMID 35667914, PMID 33083026, PMID 33440088, PMID 33524316, PMID 33704352, PMID 33882225, PMID 34824596, PMID 35081293, PMID 35139271, PMID 35798000, PMID 36113538, PMID 36357712, PMID 36732164, PMID 37385888, PMID 37433788, PMID 37992183, PMID 38467646, PMID 38705804, PMID 38918103, PMID 39121698, PMID 39225478, PMID 39532861, PMID 39866854, PMID 39868766, PMID 40298376, PMID 40808283, PMID 41289027
5UM1AI148684-02 (1)